Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma
- 1 September 2003
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 39 (13) , 1948-1956
- https://doi.org/10.1016/s0959-8049(03)00427-1
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002
- Clinical Implications of Circulating Angiogenic Factors in Cancer PatientsJournal of Clinical Oncology, 2001
- Angiogenesis in cancer and other diseasesNature, 2000
- Serum Vascular Endothelial Growth Factor in Epithelial Ovarian Neoplasms: Correlation with Patient SurvivalGynecologic Oncology, 1999
- Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant diseaseCancer, 1999
- Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinomaCancer, 1998
- Vascular endothelial growth factor serum concentrations in ovarian cancerObstetrics & Gynecology, 1998
- Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levelsBritish Journal of Cancer, 1997
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995